Cardiopulmonary Stress Testing Systems Market
Cardiopulmonary Stress Testing Systems Market Study by CPET Systems, Stress ECG, Pulse Oximeters, SPECT, and Stress Blood Pressure Monitors from 2023 to 2033
Analysis of Cardiopulmonary Stress Testing Systems Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Cardiopulmonary Stress Testing Systems Market Outlook (2023 to 2033)
The global cardiopulmonary stress testing systems market is forecasted to rise at a CAGR of 5.2% from 2023 to 2033. In 2023, the market is valued at US$ 6 billion and is thus estimated to reach a size of US$ 10 billion by the end of 2033.
Cardiopulmonary exercise testing gauges how well the heart and lungs can circulate blood. Injured athletes are tested using cardiopulmonary exercise testing systems, and cardiac output measurements are essential during operations. The cardiopulmonary bypass machine controls cardiopulmonary exercise testing systems, which operate by pumping air or air that is low in oxygen into the patient's body. This creates an increase in arterial pressure, which is followed by venous return.
An individual's heart and lung function are assessed using cardiopulmonary stress testing equipment. This data can be used to evaluate the efficacy of treatment as well as identify heart and lung disorders.
Cardiovascular Disease (CVD) remains one of the leading causes of death across the world. Limited access to monitoring and diagnosis of CVDs is attributed as a major reason for the increasing death rate. A growing geriatric population pool with CVDs and growing initiatives by government organizations to enlighten people about the accurate assessment of CVDs are anticipated to boost market expansion.
In addition, increased budgetary allocation and provision of affordable treatment to patients are burgeoning. This has encouraged market players to establish their businesses in prospective markets and introduce technologically enhanced testing systems. The market is influenced by factors such as the rising popularity of these devices due to their affordability and versatility, as well as the advantages they offer in terms of testing, such as accuracy and quick turnaround times.
The market for cardiopulmonary stress testing systems is favorably impacted by the growing elderly population, increase in disease and treatment awareness among people, research and development activities, improved healthcare infrastructure, and rise in healthcare spending. Furthermore, key market participants are expected to benefit from developments and advancements in treatment facilities over the coming years.
Rapid integration of diagnostic techniques for heart-related conditions such as arrhythmia and valve imbalance is propelling market expansion. The global market for cardiopulmonary stress testing systems is expanding as a result of factors, including rising awareness of new lifestyle diseases as well as heart and lung problems.
Other significant drivers include the growth of the portable device sector, the creation of high-sensitivity ECG equipment, the expansion of cardiovascular centers for improved diagnostics, and the low-cost deployment of new technologies in emerging economies.
The market is projected to expand as more research and development projects show the effectiveness of cardiopulmonary stress tests in identifying cardiopulmonary problems. As a result, the benefits of early diagnosis of heart disorders using stress testing would contribute to a reduction in the death rate linked to these illnesses, increasing product demand.
Report Attributes |
Details |
|
Cardiopulmonary Stress Testing Systems Market Size (2023) |
US$ 6 Billion |
|
Projected Market Value (2033) |
US$ 10 Billion |
|
Global Market Growth Rate (2023 to 2033) |
5.2% CAGR |
|
Market Share of Cardiopulmonary Exercise Testing (CPET) Systems |
50% |
|
Key Companies Profiled |
|
Why is the Need for Cardiopulmonary Stress Testing Systems Increasing Worldwide?
“Rising Prevalence of Cardiovascular Disorders and Increasing Geriatric Population”
The market for cardiopulmonary stress testing systems is anticipated to rise due to the rising incidence of cardiovascular disorders. Cardiovascular disorders (CVDs), such as coronary artery disease, ischemic heart disease, and myocardial infection, are becoming more common and prevalent worldwide. Early detection of CVDs is essential to minimizing hospital stays and lowering mortality rates. Physicians advise cardiopulmonary stress testing to identify and assess the severity of CVDs.
The cardiopulmonary stress testing systems market is expanding because of the increasing usage of cardiopulmonary stress testing devices to examine people's cardiopulmonary systems. Congenital heart defect (CHD) incidence is rising across the board. Adult patients with CHD undergo cardiopulmonary exercise tests to determine their ability to adjust to the hemodynamic demands of exercise. As a result, the market is expanding due to the rising prevalence of CHD.
Atrial fibrillation and an increase in the incidence of various cardiovascular conditions worldwide are the main causes contributing to market growth, which calls for an assessment of cardiopulmonary performance. In the European Union, more than 60 million people have cardiovascular disease, and nearly 13 million new cases are diagnosed each year. These statistics call for the adoption of stress testing procedures for the early diagnosis of heart diseases, which is estimated to drive market growth over the forecast period.
Globally, aged individuals are rising at an unprecedented rate. As a result, the risk of coronary artery disease rises along with the senior population as this population is prone to heart issues due to high total serum cholesterol levels. Global demand for cardiopulmonary stress testing systems is increasing due to rising obesity rates, the local supply of monitoring products, the introduction of advanced technologies, and the elimination of stress testing-related issues.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What Could Possibly Hinder Adoption of Cardiopulmonary Stress Testing Systems?
“High Cost of Software-based Stress Testing Solutions and Stringent Government Regulations”
Market expansion is being hampered by strict government regulations, lower physician acceptance, and the complexity of R&D. High cost of software-based stress testing solutions is expected to limit the cardiopulmonary stress testing devices market growth over the coming years, according to pricing trends.
Which Regional Market is the Most Profitable for Cardiopulmonary Stress Testing System Providers?
“Increasing Investments by Government Organizations in Medical Treatments in North America”
North America accounts for 50% share of the global market. An increase in hospital admissions, the existence of several healthcare facilities deploying novel products, and rising efficiency in accurate diagnostics of cardiovascular diseases are anticipated to leverage the market growth.
The availability of modern cardiac care services and increasing investments by government organizations for medical treatments are driving market growth in the region.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
How is Demand for Cardiopulmonary Stress Testing Systems Shaping Up in the United States?
“Expanding Use of Early Cardiopulmonary Diagnostic Procedures”
Heart disease is a common condition in the United States, according to the Centers for Disease Control and Prevention (CDC). The same source states that around 805,000 Americans experience a heart attack each year. The industry is being driven by the constant requirement for early detection due to the mortality rate from heart disorders.
Rising prevalence of cardiovascular and pulmonary problems, the presence of skilled healthcare professionals, and the introduction of novel stress testing systems are the factors driving demand for cardiopulmonary stress testing systems in the United States. An increase in the incidence of lifestyle diseases and expanding use of early cardiopulmonary diagnostic procedures are fueling market value in the country.
Why is Germany a Lucrative Market for Cardiopulmonary Stress Testing Systems?
“Increase in Geriatric Patients in the Country”
Growing demand for cardiovascular disease monitoring and diagnostic devices, an increase in geriatric patients, and surging awareness of stress testing are the elements propelling market expansion in Germany. The high adoption and penetration of advanced testing systems at public health centers and institutions that assist nurses and doctors in real-time patient health monitoring is driving market revenue in Germany.
Why is Japan Emerging as a Prominent Market for Cardiopulmonary Stress Testing Devices?
“Growing Awareness of Advantages of Cardiopulmonary Stress Testing Systems among Healthcare Practitioners”
The market in Japan is expected to have profitable growth during the projection period due to rising disposable income, and enhanced healthcare infrastructure. Increasing awareness of the advantages of cardiopulmonary stress testing systems among healthcare practitioners is driving market growth in Japan.
Category-wise Insights
Why are Cardiopulmonary Exercise Testing Systems Highly Preferred?
“Cardiopulmonary Exercise Testing Systems Gaining Traction Due to Their Precision and Cost-effectiveness”
Based on product, the market is divided into cardiopulmonary exercise testing (CPET) systems, stress ECG, pulse oximeters, single-photon emission computed tomography (SPECT), and stress blood pressure monitors. Cardiopulmonary exercise testing systems account for 50% share of the global market.
Cardiopulmonary exercise testing systems are becoming more popular because of their precision and quick operation. In addition, the cost-effectiveness and variety of uses of these devices have raised the preference among doctors and patients, which has fueled market expansion through a greater acceptance of these systems.
The most common form of cardiac screening is exercise cardiac stress testing (EST). The treadmill's speed and height are gradually increased while the patient works out on it according to a prescribed plan. Throughout the exercise cardiac stress test (EST), the patient's ECG, heart rate, heart rhythm, and blood pressure are continually analyzed.
Cardiopulmonary exercise testing systems provide a distinct and complimentary assessment by facilitating a more precise and reliable measurement of a patient’s functional capacity. They provide better validation for evaluating the prognosis of heart failure patients and measuring responses to heart failure therapy.
Cardiopulmonary exercise testing system results in early disease identification are anticipated to propel market growth through widespread implementation. New developments in artificial intelligence and wearable technologies offer exceptional prospects to expand the use of these tests and simplify their interpretation.
Which End User Generates High Revenue in This Market?
“Increasing Need for Early Detection of Cardiovascular Illnesses Driving Adoption of Cardiopulmonary Stress Testing Systems in Hospitals”
The market is divided into hospitals, specialty clinics/cardiology clinics, ambulatory surgical centers, and diagnostic centers based on end user. Hospitals are preferred due to government measures to boost hospital admissions for cardiovascular illnesses and an increasing geriatric population base with related risk factors.
Hospitals are gaining traction due to the growing preference for hospital-based treatments for the early detection of cardiovascular illnesses and an increase in stress testing procedures performed at these facilities. Hospitals have ramped up their efforts in providing top-quality medical care and reducing complications among existing patients.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Major market participants are focusing on improving product standards and adopting new methodologies following safety regulations to reduce the environmental impact. Leading companies in the global market for cardiopulmonary stress testing systems are involved in product launches, supply chain management, and joint ventures with other businesses.
Top cardiopulmonary stress testing system providers are emphasizing the quality control of smart technologies and integrated software systems to increase their competitive edge globally. Increasing investments in R&D to enhance medical equipment will boost the market for cardiopulmonary stress testing systems in developing countries.
For instance,
- Schiller AG is a pioneer in the global cardiopulmonary stress testing services market. The company is continuously improving its product pipeline and technologies for patient assessment via stress tests.
- VYAIRE MEDICAL INC., produces the Vmax and Vyntus CPX CPET devices. The latter device is equipped with a digital volume transducer (DVT) flow sensory technology, which provides an accurate and reliable flow and volume measurement of cardiac functioning.
Cardiopulmonary Stress Testing Systems Industry Research Segments
-
By Product :
- Cardiopulmonary Exercise Testing (CPET) Systems
- Stress ECG
- Pulse Oximeters
- Single-photon Emission Computed Tomography (SPECT)
- Stress Blood Pressure Monitors
-
By End User :
- Hospitals
- Specialty Clinics/Cardiology Clinics
- Ambulatory Surgical Centers
- Diagnostic Centers
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Market 4. Market Overview 4.1. Introduction 4.1.1. Product Type Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Key Market Indicators 4.4. Market Dynamics 4.4.1. Drivers 4.4.1.1. Rising awareness among end-users about accurate assessment of cardiovascular diseases due to new monitoring technologies is significantly enhancing the diagnosis rate 4.4.1.2. Growing geriatric population propels adoption of preventive disease-monitoring products 4.4.2. Restraints 4.4.2.1. Shutdown of Chalk River resulting in shortage of Tc-99 m and reduction in the number of SPECT procedures 4.4.2.2. Implementation of legal provisions that promote cost containment/cost-cutting strategies 4.4.3. Opportunity 4.5. Global Market Analysis and Forecasts, 2023–2033 4.5.1. Market Revenue Projections (US$ Mn) 4.6. Porter’s Five Force Analysis 4.7. Market Outlook 4.8. Regulatory Scenarios 4.9. Cardiovascular Diseases Prevalence, by Region 4.10. Applied SWOT Analysis 5. Global Market Analysis and Forecasts, By Product Type 5.1. Introduction & Definition 5.2. Key Findings / Developments 5.3. Key Trends 5.4. Market Value Forecast ByProduct Type, 2023–2033 5.4.1. Cardiopulmonary Exercise Testing (CPET) Systems 5.4.2. Stress ECG 5.4.3. Pulse Oximeters 5.4.4. Stress Blood Pressure Monitors 5.4.5. Single-Photon Emission Computed Tomography (SPECT) 5.5. Product Type Comparison Matrix 5.6. Market Attractiveness By Product Type 6. Global Market Analysis and Forecasts, By End-user 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Key Trends 6.4. Market Value Forecast By End-user, 2023–2033 6.4.1. Hospitals 6.4.2. Specialty Clinics/Cardiology Clinics 6.4.3. Ambulatory Surgical Centers 6.4.4. Diagnostic Centers 6.5. Market Attractiveness By End-user 7. Global Market Analysis and Forecasts, By Region 7.1. Key Findings 7.2. Policies and Regulations 7.3. Market Value Forecast By Region 7.3.1. North America 7.3.2. Europe 7.3.3. Asia Pacific 7.3.4. Latin America 7.3.5. Middle East and Africa 7.4. Market Attractiveness By Country/Region 8. North America Market Analysis and Forecast 8.1. Introduction 8.1.1. Key Findings 8.1.2. Key Trends 8.2. Market Value Forecast By Product Type, 2023–2033 8.2.1. Cardiopulmonary Exercise Testing (CPET) Systems 8.2.2. Stress ECG 8.2.3. Pulse Oximeters 8.2.4. Stress Blood Pressure Monitors 8.2.5. Single-Photon Emission Computed Tomography (SPECT) 8.3. Market Value Forecast By End-user, 2023–2033 8.3.1. Hospitals 8.3.2. Specialty Clinics/Cardiology Clinics 8.3.3. Ambulatory Surgical Centers 8.3.4. Diagnostic Centers 8.4. Market Value Forecast By Country, 2023–2033 8.4.1. U.S. 8.4.2. Canada 8.5. Market Attractiveness Analysis 8.5.1. By Product Type 8.5.2. By End-user 8.5.3. By Country 9. Europe Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.1.2. Key Trends 9.2. Market Value Forecast ByProduct Type, 2023–2033 9.2.1. Cardiopulmonary Exercise Testing (CPET) Systems 9.2.2. Stress ECG 9.2.3. Pulse Oximeters 9.2.4. Stress Blood Pressure Monitors 9.2.5. Single-Photon Emission Computed Tomography (SPECT) 9.3. Market Value Forecast By End-user, 2023–2033 9.3.1. Hospitals 9.3.2. Specialty Clinics/Cardiology Clinics 9.3.3. Ambulatory Surgical Centers 9.3.4. Diagnostic Centers 9.4. Market Value Forecast By Country/Sub-region, 2023–2033 9.4.1. U.K. 9.4.2. Germany 9.4.3. France 9.4.4. Italy 9.4.5. Spain 9.4.6. Russia 9.4.7. Rest of Europe 9.5. Market Attractiveness Analysis 9.5.1. By Product Type 9.5.2. By End-user 9.5.3. By Country/Sub-region 10. Asia Pacific Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.1.2. Key Trends 10.2. Market Value Forecast By Product Type, 2023–2033 10.2.1. Cardiopulmonary Exercise Testing (CPET) Systems 10.2.2. Stress ECG 10.2.3. Pulse Oximeters 10.2.4. Stress Blood Pressure Monitors 10.2.5. Single-Photon Emission Computed Tomography (SPECT) 10.3. Market Value Forecast By End-user, 2023–2033 10.3.1. Hospitals 10.3.2. Specialty Clinics/Cardiology Clinics 10.3.3. Ambulatory Surgical Centers 10.3.4. Diagnostic Centers 10.4. Market Value Forecast By Country/Sub-region, 2023–2033 10.4.1. India 10.4.2. China 10.4.3. Japan 10.4.4. Australia & New Zealand 10.4.5. Rest of Asia Pacific 10.5. Market Attractiveness Analysis 10.5.1. By Product Type 10.5.2. By End-user 10.5.3. By Country/Sub-region 11. Latin America Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.1.2. Key Trends 11.2. Market Value Forecast By Product Type, 2023–2033 11.2.1. Cardiopulmonary Exercise Testing (CPET) Systems 11.2.2. Stress ECG 11.2.3. Pulse Oximeters 11.2.4. Stress Blood Pressure Monitors 11.2.5. Single-Photon Emission Computed Tomography (SPECT) 11.3. Market Value Forecast By End-user, 2023–2033 11.3.1. Hospitals 11.3.2. Specialty Clinics/Cardiology Clinics 11.3.3. Ambulatory Surgical Centers 11.3.4. Diagnostic Centers 11.4. Market Value Forecast By Country/Sub-region, 2023–2033 11.4.1. Brazil 11.4.2. Mexico 11.4.3. Rest of Latin America 11.5. Market Attractiveness Analysis 11.5.1. By Product Type 11.5.2. By End-user 11.5.3. By Country/Sub-region 12. Middle East and Africa Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.1.2. Key Trends 12.2. Market Value Forecast By Product Type, 2023–2033 12.2.1. Cardiopulmonary Exercise Testing (CPET) Systems 12.2.2. Stress ECG 12.2.3. Pulse Oximeters 12.2.4. Stress Blood Pressure Monitors 12.2.5. Single-Photon Emission Computed Tomography (SPECT) 12.3. Market Value Forecast By End-user, 2023–2033 12.3.1. Hospitals 12.3.2. Specialty Clinics/Cardiology Clinics 12.3.3. Ambulatory Surgical Centers 12.3.4. Diagnostic Centers 12.4. Market Value Forecast By Country/Sub-region, 2023–2033 12.4.1. South Africa 12.4.2. GCC Countries 12.4.3. Israel 12.4.4. Rest of Middle East and Africa 12.5. Market Attractiveness Analysis 12.5.1. By Product Type 12.5.2. By End-user 12.5.3. By Country/Sub-region 13. Competition Landscape 13.1. Market Player – Competition Matrix (By Tier and Size of companies) 13.2. Market Share Analysis By Company (2022) 13.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy) 13.3.1. Koninklijke Philips N.V. 13.3.1.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.1.2. Financial Overview 13.3.1.3. SWOT Analysis 13.3.1.4. Strategic Overview 13.3.2. Hill-Rom Holdings, Inc. (Welch Allyn & Mortara Instrument, Inc.) 13.3.2.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.2.2. Financial Overview 13.3.2.3. Product Portfolio 13.3.2.4. SWOT Analysis 13.3.2.5. Strategic Overview 13.3.3. General Electric Company (GE Healthcare) 13.3.3.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.3.2. Financial Overview 13.3.3.3. Product Portfolio 13.3.3.4. SWOT Analysis 13.3.3.5. Strategic Overview 13.3.4. MGC Diagnostics Corporation 13.3.4.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.4.2. Financial Overview 13.3.4.3. Product Portfolio 13.3.4.4. SWOT Analysis 13.3.4.5. Strategic Overview 13.3.5. OSI Systems, Inc. (Spacelabs Healthcare) 13.3.5.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.5.2. Financial Overview 13.3.5.3. Product Portfolio. 13.3.5.4. SWOT Analysis 13.3.5.5. Strategic Overview 13.3.6. Masimo 13.3.6.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.6.2. Financial Overview 13.3.6.3. Product Portfolio 13.3.6.4. SWOT Analysis 13.3.6.5. Strategic Overview 13.3.7. NIHON KOHDEN CORPORATION 13.3.7.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.7.2. Financial Overview 13.3.7.3. Product Portfolio 13.3.7.4. SWOT Analysis 13.3.7.5. Strategic Overview 13.3.8. COSMED 13.3.8.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.8.2. Financial Overview 13.3.8.3. Product Portfolio 13.3.8.4. SWOT Analysis 13.3.8.5. Strategic Overview 13.3.9. Halma plc (SunTech Medical, Inc.) 13.3.9.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.9.2. Financial Overview 13.3.9.3. Product Portfolio 13.3.9.4. SWOT Analysis 13.3.9.5. Strategic Overview 13.3.10. Schiller AG 13.3.10.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.10.2. Financial Overview 13.3.10.3. Product Portfolio 13.3.10.4. SWOT Analysis 13.3.10.5. Strategic Overview 13.3.11. Vyaire Medical, Inc. 13.3.11.1. Company Overview (HQ, Business Segments, Employee Strengths) 13.3.11.2. Financial Overview 13.3.11.3. Product Portfolio 13.3.11.4. SWOT Analysis 13.3.11.5. Strategic Overview
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Medical Device Classification as per U.S. FDA
Table 02: Code of Federal Regulations, by Type of Device
Table 03: Supplements for Pre-market Approval, by Type of Supplement, 1986–1997
Table 04: Medical Device Classification as per European Commission (EC)
Table 05: Global Market Value (US$ Mn) Forecast, by Product Type, 2023–2033
Table 06: Global Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 07: Global Market Size (US$ Mn) Forecast, by Region, 2023–2033
Table 08: North America Market Value (US$ Mn) Forecast, by Country, 2023–2033
Table 09: North America Market Value (US$ Mn) Forecast, by Product Type, 2023–2033
Table 10: North America Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 11: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 12: Europe Market Value (US$ Mn) Forecast, by Product Type, 2023–2033
Table 13: Europe Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 14: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 15: Asia Pacific Market Value (US$ Mn) Forecast, by Product Type, 2023–2033
Table 16: Asia Pacific Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 17: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 18: Latin America Market Value (US$ Mn) Forecast, by Product Type, 2023–2033
Table 19: Latin America Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 20: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 21: Middle East & Africa Market Value (US$ Mn) Forecast, by Product Type, 2023–2033
Table 22: Middle East & Africa Market Value (US$ Mn) Forecast, by End-user, 2023–2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Forecast, 2023–2033
Figure 02: Global Market Value Share, by Product (2022)
Figure 03: Global Market Value Share, by Region (2022)
Figure 04: Global Market Value Share, by End-user (2022)
Figure 05: FDA Review Process for 2022
Figure 06: Deaths per Mn Population Caused by Cardiovascular Diseases, by Country, 2012
Figure 07: Global Market Value Share, by Product Type, 2023 and 2033
Figure 08: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Cardiopulmonary Exercise Testing (CPET) Systems, 2023–2033
Figure 09: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Stress ECG, 2023–2033
Figure 10: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Pulse Oximeters, 2023–2033
Figure 11: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Stress Blood Pressure Monitors, 2023–2033
Figure 12: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Single-Photon Emission Computed Tomography (SPECT), 2023–2033
Figure 13: Global Market Attractiveness, by Product Type, 2023–2033
Figure 14: Global Market Value Share, by End-user, 2023 and 2033
Figure 15: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospitals, 2023–2033
Figure 16: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Specialty Clinics/ Cardiology Clinics, 2023–2033
Figure 17: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Ambulatory Surgical Centers, 2023–2033
Figure 18: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Diagnostic Centers, 2023–2033
Figure 19: Global Market Attractiveness, by End-user, 2023–2033
Figure 20: Global Market Value Share, by Region, 2023 and 2033
Figure 21: Global Market Attractiveness, by Region, 2023–2033
Figure 22: North America Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033
Figure 23: North America Market Value Share, by Country, 2023 and 2033
Figure 24: North America Market Attractiveness, by Country, 2023–2033
Figure 25: North America Market Value Share, by Product Type, 2023 and 2033
Figure 26: North America Market Attractiveness, by Product Type, 2023–2033
Figure 27: North America Market Value Share, by End-user, 2023 and 2033
Figure 28: North America Market Attractiveness, by End-user, 2023–2033
Figure 29: Europe Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033
Figure 30: Europe Market Value Share, by Country/Sub-region, 2023 and 2033
Figure 31: Europe Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 32: Europe Market Value Share, by Product Type, 2023 and 2033
Figure 33: Europe Market Attractiveness, by Product Type, 2023–2033
Figure 34: Europe Market Value Share, by End-user, 2023 and 2033
Figure 35: Europe Market Attractiveness, by End-user, 2023–2033
Figure 36: Asia Pacific Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033
Figure 37: Asia Pacific Market Value Share, by Country/Sub-region, 2023 and 2033
Figure 38: Asia Pacific Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 39: Asia Pacific Market Value Share, by Product Type, 2023 and 2033
Figure 40: Asia Pacific Market Attractiveness, by Product Type, 2023–2033
Figure 41: Asia Pacific Market Value Share, by End-user, 2023 and 2033
Figure 42: Asia Pacific Market Attractiveness, by End-user, 2023–2033
Figure 43: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033
Figure 44: Latin America Market Value Share, by Country/Sub-region, 2023 and 2033
Figure 45: Latin America Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 46: Latin America Market Value Share, by Product Type, 2023 and 2033
Figure 47: Latin America Market Attractiveness, by Product Type, 2023–2033
Figure 48: Latin America Market Value Share, by End-user, 2023 and 2033
Figure 49: Latin America Market Attractiveness, by End-user, 2023–2033
Figure 50: Middle East & Africa Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033
Figure 51: Middle East & Africa Market Value Share, by Country/Sub-region, 2023 and 2033
Figure 52: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 53: Middle East & Africa Market Value Share, by Product Type, 2023 and 2033
Figure 54: Middle East & Africa Market Attractiveness, by Product Type, 2023–2033
Figure 55: Middle East & Africa Market Value Share, by End-user, 2023 and 2033
Figure 56: Middle East & Africa Market Attractiveness, by End-user, 2023–2033
Figure 57: Global Market Share, by Company, 2022
Figure 58: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Koninklijke Philips N.V.
Figure 59: R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Koninklijke Philips N.V.
Figure 60: Sales & Marketing Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Koninklijke Philips N.V.
Figure 61: Breakdown of Net Sales (%), by Region, 2022, Koninklijke Philips N.V.
Figure 62: Breakdown of Net Sales (%), by Business Segment, 2022, Koninklijke Philips N.V.
Figure 63: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Hill-Rom Holdings, Inc. (Welch Allyn & Mortara Instrument, Inc.)
Figure 64: R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Hill-Rom Holdings, Inc. (Welch Allyn & Mortara Instrument, Inc.)
Figure 65: Selling and Administrative Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Hill-Rom Holdings, Inc. (Welch Allyn & Mortara Instrument, Inc.)
Figure 66: Breakdown of Net Sales (%), by Region, 2022 (Hill-Rom Holdings, Inc.)
Figure 67: Breakdown of Net Sales (%), by Business Segment, 2022 (Hill-Rom Holdings, Inc.)
Figure 68: Breakdown of Net Sales (%), by Region, 2018 (Welch Allyn)
Figure 69: Breakdown of Net Sales (~ %), by Business Segments, 2022 (Mortara Instrument, Inc.)
Figure 70: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022, General Electric Company (GE Healthcare)
Figure 71: R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, General Electric Company (GE Healthcare)
Figure 72: Selling and Administrative Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, General Electric Company (GE Healthcare)
Figure 73: Breakdown of Net Sales (%), by Region, 2022, General Electric Company (GE Healthcare)
Figure 74: Breakdown of Net Sales (%), by Business Segment, 2022, General Electric Company (GE Healthcare)
Figure 75: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022, MGC Diagnostics Corporation
Figure 76: R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, MGC Diagnostics Corporation
Figure 77: Sales & Marketing Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, MGC Diagnostics Corporation
Figure 78: Breakdown of Net Sales (%), by Region, 2022, MGC Diagnostics Corporation
Figure 79: Breakdown of Net Sales (%), by Business Segment, 2022, MGC Diagnostics Corporation
Figure 80: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022, OSI Systems, Inc. (Spacelabs Healthcare)
Figure 81: R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, OSI Systems, Inc. (Spacelabs Healthcare)
Figure 82: Selling and Administrative Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, OSI Systems, Inc. (Spacelabs Healthcare)
Figure 83: Breakdown of Net Sales (%), by Region, 2022, OSI Systems, Inc. (Spacelabs Healthcare)
Figure 84: Breakdown of Net Sales (%), by Business Segment, 2022, OSI Systems, Inc. (Spacelabs Healthcare)
Figure 85: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Masimo
Figure 86: R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Masimo
Figure 87: Selling and Administrative Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Masimo
Figure 88: Breakdown of Net Sales (%), by Region, 2022, Masimo
Figure 89: Installed Base (Estimated Units) and Y-o-Y Growth (%), 2018–2022, Masimo
Figure 90: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022, NIHON KOHDEN CORPORATION
Figure 91: R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, NIHON KOHDEN CORPORATION
Figure 92: Selling and Administrative Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022, NIHON KOHDEN CORPORATION
Figure 93: Breakdown of Net Sales (%), by Region, 2022, NIHON KOHDEN CORPORATION
Figure 94: Breakdown of Net Sales (%), by Business Segment, 2022, NIHON KOHDEN CORPORATION
Figure 95: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Halma plc (SunTech Medical, Inc.)
Figure 96: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022, Halma plc (SunTech Medical, Inc.)
Figure 97: Breakdown of Net Sales (%), by Business Segment, 2022, Halma plc (SunTech Medical, Inc.)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
At what CAGR is the cardiopulmonary stress testing systems market expected to progress through 2033?
Adoption of cardiopulmonary stress testing systems is set to increase at a CAGR of 5.2% through 2033.
Which product accounts for a leading market share?
Cardiopulmonary exercise testing systems hold 50% share of the global cardiopulmonary stress testing systems market.
Which are the major countries driving high demand for cardiopulmonary stress testing systems?
The U.S., Germany, and Japan are key countries in the market for cardiopulmonary stress testing equipment.
What is the forecasted size of the cardiopulmonary stress testing systems market?
Worldwide demand for cardiopulmonary stress testing systems is forecasted to reach US$ 10 billion by 2033.
Who are the top providers of cardiopulmonary stress testing systems?
Schiller AG, Allengers, and COSMED srl are major suppliers of cardiopulmonary stress testing systems.
Cardiopulmonary Stress Testing Systems Market